Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs

Palella, 1998, Declining morbidity and mortality among patients with advanced HIV infection. HIV Outpatient Study Investigators., N Engl J Med, 338, 853, 10.1056/NEJM199803263381301

2000, Survival after introduction of HAART in people with known duration of HIV-1 infection., Lancet, 355, 1158, 10.1016/S0140-6736(00)02069-9

Martin-Carbonero, 2001, Increasing impact of chronic viral hepatitis on hospital admission and mortality among HIV-infected patients., AIDS Res Hum Retroviruses, 17, 1467, 10.1089/08892220152644160

Bica, 2001, Increasing mortality due to end-stage liver disease in patients with HIV infection., Clin Infect Dis, 32, 492, 10.1086/318501

Rosenthal, 2003, Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)., AIDS, 17, 1803, 10.1097/00002030-200308150-00009

Duffy, 1986, Hepatitis in children with AIDS: histopathologic and immunocytologic features., Gastroenterology, 90, 173, 10.1016/0016-5085(86)90090-9

Walker, 2004, Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine or zalcitabine., Hepatology, 39, 311, 10.1002/hep.20074

Skelly, 2001, Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology., J Hepatol, 35, 195, 10.1016/S0168-8278(01)00094-0

Weiss, 2004, Real time TaqMan PCR detection and quantification of HBV genotypes A-G with the use of an internal quantitation standard., J Clin Virol, 30, 86, 10.1016/j.jcv.2003.08.015

Konnick, 2005, Evaluation of the COBAS hepatitis C virus TaqMan specific reagent assay and comparison to the COBAS Amplicor HCV Monitor v2.0 and Versant HCV bDNA v3.0 assays., J Clin Microbiol, 43, 2133, 10.1128/JCM.43.5.2133-2140.2005

Gartner, 2004, Evaluation of a new automated, standardized generic nucleic acid extraction method used in combination with cytomegalovirus DNA quantification by COBAS Amplicor CMV Monitor., J Clin Microbiol, 42, 3881, 10.1128/JCM.42.8.3881-3882.2004

Koidl, 2004, Detection of transfusion-transmitted virus DNA by real-time PCR., J Clin Virol, 29, 277, 10.1016/S1386-6532(03)00168-9

Sandrin, 2003, Transient elastography: a new non-invasive method for assessment of hepatic fibrosis., Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001

Castera, 2005, Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C., Gastroenterology, 128, 343, 10.1053/j.gastro.2004.11.018

Greeve, 1993, Cirrhosis of undefined pathogenesis: absence of evidence for unknown viruses or autoimmune processes., Hepatology, 17, 593, 10.1002/hep.1840170411

Caldwell, 1999, Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease., Hepatology, 29, 664, 10.1002/hep.510290347

Caldwell, 2004, The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease., J Hepatol, 40, 578, 10.1016/j.jhep.2004.02.013

De Mendoza, 2005, Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin., Antivir Ther, 9, 345

Gonzalez-Scarano, 2005, The neuropathogenesis of AIDS., Nat Rev Immunol, 5, 69, 10.1038/nri1527

Lu, 2005, HIV-associated nephropathy. A brief review., Mt Sinai J Med, 72, 193

Giovanni, 2005, HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiretroviral therapy., Dig Dis Sci, 50, 617, 10.1007/s10620-005-2545-5

Nunez, 2005, Hepatotoxicity of antiretrovirals: incidence, mechanisms and management., Drug Saf, 28, 53, 10.2165/00002018-200528010-00004

Sanne, 2005, Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects., J Infect Dis, 191, 825, 10.1086/428093

Gonzalez de Requena, 2002, Liver toxicity caused by nevirapine., AIDS, 16, 290, 10.1097/00002030-200201250-00020

Martinez, 2001, Hepatotoxicity in HIV-1 infected patients receiving nevirapine containing antiretroviral therapy., AIDS, 15, 1261, 10.1097/00002030-200107060-00007

Nunez, 2003, Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients., AIDS Res Hum Retroviruses, 19, 187, 10.1089/088922203763315687

Macias, 2004, Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine., AIDS, 18, 767, 10.1097/00002030-200403260-00007

Benhamou, 2001, Factors affecting liver fibrosis in HIV and hepatitis C virus coinfected patients: impact of protease inhibitor therapy., Hepatology, 34, 283, 10.1053/jhep.2001.26517

Fuster, 2004, Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy., AIDS Res Hum Retroviruses, 20, 1293, 10.1089/aid.2004.20.1293

Marine-Barjoan, 2004, Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients., AIDS, 18, 2163, 10.1097/00002030-200411050-00008

Qurishi, 2003, Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection., Lancet, 362, 1708, 10.1016/S0140-6736(03)14844-1

Bonacini, 2004, Survival in patients with HIV infection and viral hepatitis B or C., AIDS, 18, 2039, 10.1097/00002030-200410210-00008

Nunez, 2004, How effective is HAART in HCV and HIV coinfection., AIDS, 18, 2081, 10.1097/00002030-200410210-00013

Clark, 2002, Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases., J Hepatol, 36, 295, 10.1016/S0168-8278(01)00291-4

Nunez, 2005, Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients., J Hepatol, 42, 290, 10.1016/j.jhep.2004.12.011

Setzer, 2005, Effects of didanosine-related depletion of mtDNA in human T lymphocytes., J Infect Dis, 191, 848, 10.1086/427655

Lee, 2003, Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase., Biochemistry, 42, 14711, 10.1021/bi035596s

Mauss, 2004, Risk factors for hepatic decompensation in patients with HIV-HCV coinfection and liver cirrhosis during interferon-based therapy., AIDS, 18, F21, 10.1097/00002030-200409030-00002

Lai, 1991, Fulminant hepatic failure associated with 2,3-dideoxyinosine (ddI)., Ann Intern Med, 115, 283, 10.7326/0003-4819-115-4-283

Bissuel, 1994, Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy., J Intern Med, 235, 367, 10.1111/j.1365-2796.1994.tb01088.x

Foli, 1997, Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine., Antivir Ther, 2, 31

Lafeuillade, 2001, Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection., Lancet, 357, 280, 10.1016/S0140-6736(00)03618-7

Guyader, 2002, Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C., J Hepatol, 37, 289, 10.1016/S0168-8278(02)00133-2

Bani-Sadr, 2005, Risk factors for symptomatic mitochondrial toxicity in HIV/HCV-coinfected patients during interferon plus ribavirin-based therapy., J Acquir Immune Defic Syndr, 40, 47, 10.1097/01.qai.0000174649.51084.46

Lacaille, 1999, Clinical utility of liver biopsy in children with acquired immunodeficiency syndrome., Pediatr Infect Dis J, 18, 143, 10.1097/00006454-199902000-00011

Arvanitaki, 2001, Nodular regenerative hyperplasia of the liver-a review of 14 cases., Hepatogastroenterology, 48, 1425

Daniel, 2005, Azathioprine induced nodular regenerative hyperplasia in IBD patients., Gastroenterol Clin Biol, 29, 600, 10.1016/S0399-8320(05)82136-0

De Bruyne, 2006, Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia., J Hepatol, 44, 407, 10.1016/j.jhep.2005.06.020

Ibarrola, 2003, Clinico-pathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate., Histopathology, 42, 251, 10.1046/j.1365-2559.2003.01586.x

Veazey, 2004, Getting to the guts of HIV pathogenesis., J Exp Med, 6, 697, 10.1084/jem.20041464